Skip to content
MarketScale
‹ Back to IndustriesHealthcare

AI and DNA: Why Healthcare Professionals are Using Analytics and Automation

The ways in which technology is going to transform the healthcare industry is significant and already underway. Many people currently use apps to track their blood sugar, heart rate, sleep, and movements, but that is only the tip of the technology transforming healthcare. Hardware and Software For technology, data is central, meaning analytics will be…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The ways in which technology is going to transform the healthcare industry is significant and already underway. Many people currently use apps to track their blood sugar, heart rate, sleep, and movements, but that is only the tip of the technology transforming healthcare.

Hardware and Software

For technology, data is central, meaning analytics will be needed to make sense of that information. The use of analytics will help potential patients make better decisions based on the most objective data possible. The more information patients have about their bodies, habits and needs, the better they will be able to make intelligent choices about their own healthcare.

Artificial Intelligence (AI) remains a truly relevant choice, but the industry is getting closer and closer to using it to revolutionize healthcare. With AI, it will be easier to track every aspect of patients’ care and well-being, coordinate doctors’ and nurses’ actions and schedules, and keep track of and detect patterns physicians and nurses may miss.

For AI to change the way hospitals operate, the industry is going to have to continue to develop the Internet of Medical Things (IoMT). The more connected medical devices are to each other and to a database covering each patient, the more complex and holistic medical care can become. This will be especially true with the development of internal monitors that will allow the healthcare system to monitor health. IoMT will allow doctors to become much more personable in their treatments and in the uses of medication.

Another potential game-changer is the use of blockchain. Blockchain is a decentralized ledger system that would simultaneously eliminate the silos around patient data and protect that data even better than those silos could. Patient data would be more secure than ever, and at the same time that data would be universally available to doctors and hospitals in an instant. This will have to wait for the regulations surrounding such data to get up to date with the technology.

Virtual Reality (VR) is also an important development that will allow doctors to try out various approaches before having to actually bring a patient into a surgical procedure. This will work in coordination with MRI, CAT scans, X-rays, and other imaging devices.

DNA All the Way

Developments in genetic technologies are also going to be game-changers in healthcare. The more professionals learn about genetics, the more the industry will learn how individualized healthcare should really be. Equally though, that means knowing more about the genetics of each particular patient. On a more individualized basis, a DNA analysis can determine how patients will react to a wide variety of drugs. Also, updates are expected in gene therapy, especially with the advent of CRISPR technology that allows for the removal of very precise sections of DNA.

Overall, the healthcare industry is seeing improvements in technology that allow for more precision, more individual care, and increased patient information and choice. From technologies that allow diabetics to have an artificial pancreas through very precise monitoring and automatic injections, to a better understanding of how the brain is wired and helps reduce anxiety or cure addiction, the potential from improved technology will change healthcare.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512